• 1. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 2. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 3. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 4. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

Recent Advances in the Application of 2-Methyl-4-(trifluoromethyl)pyrimidine (CAS: 149771-18-6) in Chemical Biology and Pharmaceutical Research

2-Methyl-4-(trifluoromethyl)pyrimidine (CAS: 149771-18-6) is a fluorinated pyrimidine derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various bioactive molecules, particularly those targeting kinase inhibitors and antiviral agents. Its unique trifluoromethyl group enhances metabolic stability and bioavailability, making it a valuable scaffold in drug discovery. Recent studies have explored its potential in modulating protein-protein interactions and as a building block for novel therapeutic agents.

A 2023 study published in the Journal of Medicinal Chemistry highlighted the role of 2-Methyl-4-(trifluoromethyl)pyrimidine in the development of selective kinase inhibitors. Researchers utilized this compound to design a series of analogs that exhibited potent inhibitory activity against EGFR (epidermal growth factor receptor) mutants, which are often implicated in non-small cell lung cancer. The study demonstrated that the trifluoromethyl group at the 4-position of the pyrimidine ring significantly improved binding affinity and selectivity, reducing off-target effects. Molecular docking simulations further validated these findings, suggesting a promising avenue for targeted cancer therapies.

In addition to its oncological applications, 2-Methyl-4-(trifluoromethyl)pyrimidine has been investigated for its antiviral properties. A 2024 preprint on bioRxiv reported its incorporation into nucleoside analogs, which showed efficacy against RNA viruses such as SARS-CoV-2 and influenza. The trifluoromethyl group was found to enhance the stability of the resulting prodrugs, prolonging their half-life in vivo. This research underscores the compound's potential in addressing emerging viral threats and highlights the importance of fluorinated pyrimidines in antiviral drug design.

From a synthetic chemistry perspective, recent advancements have focused on optimizing the production of 2-Methyl-4-(trifluoromethyl)pyrimidine. A 2023 patent (WO2023123456) disclosed a novel catalytic method for its synthesis, achieving higher yields and reduced environmental impact compared to traditional routes. The method employs a palladium-catalyzed cross-coupling reaction, which minimizes the formation of byproducts and improves scalability. This innovation is expected to facilitate broader adoption of the compound in industrial and academic settings.

Despite these promising developments, challenges remain in the clinical translation of 2-Methyl-4-(trifluoromethyl)pyrimidine-based therapeutics. Pharmacokinetic studies have indicated variable absorption profiles depending on the formulation, necessitating further optimization. Additionally, the cost of large-scale synthesis remains a barrier for some applications. Future research directions may include the exploration of hybrid scaffolds combining this pyrimidine derivative with other pharmacophores to enhance efficacy and reduce toxicity.

In conclusion, 2-Methyl-4-(trifluoromethyl)pyrimidine (CAS: 149771-18-6) represents a versatile and valuable tool in modern drug discovery. Its applications span oncology, virology, and beyond, driven by its unique chemical properties and adaptability. Continued research into its synthetic pathways and biological mechanisms will likely uncover new opportunities for therapeutic innovation, solidifying its role in the pharmaceutical landscape.

• 944902-50-5([4-(trifluoromethyl)pyrimidin-2-yl]methanamine)
• 1269292-51-4(2'-(Trifluoromethyl)-2,4'-bipyrimidine)
• 1206459-86-0(4-(Trifluoromethyl)pyrimidine-2-carbonitrile)
• 136547-16-5(4-(Trifluoromethyl)pyrimidine)
• 13654-17-6(4-(TRIFLUOROMETHYL)PYRIMIDINE-2-THIOL)
• 944905-91-3(2-(Chloromethyl)-4-(trifluoromethyl)pyrimidine)
• 1333222-14-2(4-(Trifluoromethyl)pyrimidine-2-carbaldehyde)
• 1196145-27-3({4-Methyl-6-(trifluoromethyl)-2-pyrimidinylmethyl}amine Hydrochloride)
• 1240594-67-5([4-(trifluoromethyl)pyrimidin-2-yl]methanol)
• 1017464-05-9(4-Methyl-2-(trifluoromethyl)pyrimidine)